Aug 9, 2012
Philips, Celsion to initiate study of ThermoDox and MR-HIFU in bone cancer
ANDOVER, MA and LAWRENCEVILLE, NJ, USA, 7 August 2012 – Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to initiate a clinical study supporting a joint development program for Celsion’s ThermoDox® combined with Philips' Sonalleve MR-HIFU (MR-guided high intensity focused ultrasound) technology for the palliation of painful metastases to the bone caused by lung, prostate or breast cancers. The companies expect to initiate a Phase 2 study in this indication in the second half of 2012.
ThermoDox® combined with MR-HIFU will be investigated for pain palliation in patients with bone metastasis. Cancer progresses to the bone in a majority of patients with late-stage breast, prostate or lung cancer, with estimates of between 300,000 to 500,000 cases annually in the United States. Patients may experience excruciating and unrelenting pain, often treated with opiate drugs and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) with only modest benefit. External beam radiation therapy is effective in palliating painful bone metastasis, but is limited by accumulating toxic effects to normal organs.
Philips’ MR-HIFU system has the potential to precisely and non-invasively target lesions with acoustic energy, creating sufficient heat to activate ThermoDox® and preferentially release high concentrations of doxorubicin in the targeted treatment area. Celsion is developing the combination of ThermoDox® and MR-HIFU through a joint research agreement with Philips Healthcare, a division of Royal Philips Electronics.
“The combination of Philips’ MR-HIFU system, a high-precision, heat-based therapy, and ThermoDox®, a heat-triggered oncolytic agent, holds great potential in that it gives us the ability to combine non-invasive thermal treatment with local delivery of high concentrations of potent, well-characterized anti-cancer drugs directly in a target area," said Falko Busse, vice president and general manager, MR Therapy for Philips Healthcare. "This multi-modality approach could be transformative for the treatment of a number of cancers. We remain excited about our collaboration with Celsion, and look forward to beginning the clinical study as soon as possible."
“Celsion is excited to evaluate ThermoDox® in combination with MR-HIFU as a next generation, non-invasive treatment for a variety of cancers; a logical step to expand ThermoDox’s great potential in oncology. FDA’s clearance to clinically study the combination of ThermoDox and MR-HIFU is a cornerstone of this joint Celsion/Philips effort,” said Michael H. Tardugno, Celsion’s president and chief executive officer. “As a recognized world leader in health care technology, Philips brings tremendous resources to this development pathway for ThermoDox®, optimizing its role in cutting edge medicine.”
About ThermoDox® and Philips’ Sonalleve MR-HIFU
ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, being evaluated in multiple clinical trials. The lead program, known as the HEAT Study, a 700-patient Phase III clinical trial in patients with hepatocellular carcinoma, also known as primary liver cancer, is fully enrolled with data expected in the fourth quarter of 2012. Doxorubicin, Thermodox’s active agent, is an approved and frequently used oncology drug for the treatment of a wide range of cancers.
The Philips Sonalleve MR-HIFU system is currently commercially available in Europe and some other countries for the treatment of uterine fibroids, a prevalent condition in women of childbearing age and palliative treatments to relieve pain associated with bone metastasis. It is not available for sale in the USA.